Only studies with real citations are listed. Empty results mean we have not attached a sourced card yet — not that unpublished claims are true.
The underlying references also appear on the sources page.
2016 · Human clinical trial · semaglutide
The trial reported a lower rate of the primary composite cardiovascular outcome with semaglutide than with placebo in the studied population. Labeling should be used for current approved indications.
View study →2021 · Human clinical trial · semaglutide
The trial reported greater mean weight reduction with semaglutide than placebo in the studied population. This is clinical trial evidence for a specific regimen, not personalized dosing advice.
View study →2021 · Human clinical trial · tirzepatide, semaglutide
The trial reported greater reductions in glycated hemoglobin with tirzepatide than with the semaglutide comparator used in the study. Cross-trial or off-label comparisons should not be inferred.
View study →2022 · Human clinical trial · tirzepatide
The trial reported substantially greater mean weight reduction with tirzepatide than placebo in the studied population.
View study →2010 · Human clinical trial · tesamorelin
Pooled analysis reported reductions in visceral adipose tissue with tesamorelin versus placebo in the studied HIV lipodystrophy population.
View study →2019 · Human clinical trial · tesamorelin
The randomized trial reported reductions in hepatic fat with tesamorelin compared with placebo in the studied population. This is not an FDA indication summary; see labeling for approved use.
View study →2006 · Human clinical trial · cjc-1295
The study reported prolonged stimulation of GH and IGF-I secretion after CJC-1295 in healthy adults. This is early human pharmacology, not an efficacy trial for a disease indication.
View study →1998 · Animal study · ipamorelin
The paper described ipamorelin as a selective GH secretagogue in experimental models, with limited ACTH/cortisol-related activity compared with some older compounds in those models.
View study →2007 · Review · bpc-157
The review summarizes a wide range of preclinical observations. These summaries are not equivalent to proven clinical effectiveness in people.
View study →2025 · Review · bpc-157
The authors report extensive preclinical literature and extremely limited human data, and conclude the compound should be considered investigational until adequate clinical trials exist.
View study →2015 · Animal study · mots-c
The study reported metabolic effects of MOTS-c in mice and cells, including findings related to insulin sensitivity and obesity models. These are preclinical results.
View study →